Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease

American Journal of Respiratory and Critical Care Medicine

Volumn 180, Issue 8, 2009, Pages 741-750

  Welte, Tobias ^a   Miravitlles, Marc ^b   Hernandez, Paul ^c   Eriksson, Göran ^d,e   Peterson, Stefan ^e   Polanowski, Tomasz ^e   Kessler, Romain ^f  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^c DALHOUSIE UNIVERSITY   (Canada)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e ASTRAZENECA R AND D   (Sweden)

^f UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Budesonide formoterol; Exacerbations; Morning activities; Morning symptoms; Tiotropium

Indexed keywords

ANTIBIOTIC AGENT; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; PLACEBO; TERBUTALINE; TIOTROPIUM BROMIDE;

ADULT; AGED; ARTICLE; BACTERIAL INFECTION; BRONCHITIS; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DAILY LIFE ACTIVITY; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPHONIA; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; HEALTH STATUS; HEART PALPITATION; HUMAN; HYPERTENSION; INSPIRATORY CAPACITY; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; PAIN; PATIENT COMPLIANCE; PEAK EXPIRATORY FLOW; PLEURITIC PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SPIROMETRY; THRUSH; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; ADRENERGIC BETA-AGONISTS; ADULT; AGED; AGED, 80 AND OVER; BUDESONIDE; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ETHANOLAMINES; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; SCOPOLAMINE DERIVATIVES;

EID: 70349854706     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200904-0492OC     Document Type: Article

References (36)

1. Rodriguez-Roisin R, Rabe KF, Anzueto A, Bourbeau J, Calverley P, Casas A, deGuia TS, Fukuchi Y, Hui DSC, Jenkins J, et al.; Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global strategy for diagnosis, management, and prevention of chronic obstructive pulmonary disease [Internet]. Bethesda, MD: NHLBI; 2008 (Accessed 2009 July 28). Available from: http://WWW.goldcopd.com/ Guidelineitem.asp?l1=2&12=1&intId=2003
2. Aalbers R, Ayres J, Backer V, Decramer M, Lier PA, Magyar P, Malolepszy J, Ruffin R, Sybrecht GW. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002;19:936-943. (Pubitemid 34567910)
3. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002;19:217-224. (Pubitemid 34162820)
4. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999;115:957-965.
5. van Noord JA, Aumann JL, Janssens E, Verhaert J, Smeets JJ, Mueller A, Cornelissen PJ. Effects of tiotropium with and without formoterol on airflow obstruction and resting hyperinflation in patients with COPD. Chest 2006;129:509-517.
6. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA Jr, Korducki L, Cassino C, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med 2005;143:317-326. (Pubitemid 41266605)
7. O'Donnell DE, Flüge T, Gerken F, Hamilton A, Webb K, Aguilanin B, Magnussen H. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in COPD. Eur Respir J 2004;23:832-840. (Pubitemid 38807355)
8. National Institute for Clinical Excellence. Chronic obstructive pulmonary disease (clinical guideline 12). London: National Institute for Clinical Excellence; 2004.
9. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003;22:912-919. (Pubitemid 37540641)
10. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003;21:74-81. (Pubitemid 36150304)
11. Calverley PMA, Anderson JA, Celli B, Ferguson GT, Jenkins C, Jones PW, Yates JC, Vestbo J; TORCH Investigators. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med 2007;356:775-789. (Pubitemid 46294610)
12. Calverley PM, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003;361:449-456. (Pubitemid 36173708)
13. 2-agonists in the prevention of exacerbations in COPD. Int J Chron Obstruct Pulmon Dis 2006;1:345-354.
14. Halpin DM, Peterson S, Larsson TP, Calverley PM. Identifying COPD patients at increased risk of mortality: predictive value of clinical study baseline data. Respir Med 2008;102:1615-1624.
15. Cazzola M, Ando F, Santus P, Ruggeri P, Di Marco F, Sanduzzi A, D'Amato M. A pilot study to assess the effects of combining fluticasone propionate/salmeterol and tiotropium on the airflow obstruction of patients with severe-to-very severe COPD. Pulm Pharmacol Ther 2007;20:556-561. (Pubitemid 47077647)
16. Tashkin DP, Celli B, Senn S, Burkhart D, Kesten S, Menjoge S, Decramer M. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med 2008;359:1543-1554.
17. Aaron SD, Vandemheen KL, Fergusson D, Maltais F, Bourbeau J, Goldstein R, Balter M, O'Donnell D, McIvor A, Sharma S, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2007;146:545-555. (Pubitemid 351650535)
18. Perng DW, Wu CC, Su KC, Lee YC, Perng RP, Tao CW. Additive benefits of tiotropium in COPD patients treated with long-acting β agonists and corticosteroids. Respirology 2006;11:598-602. (Pubitemid 44186266)
19. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of "triple" therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63:592-598.
20. Barnes PJ. How corticosteroids control inflammation: Quintiles Prize Lecture 2005. Br J Pharmacol 2006;148:245-254.
21. Bourbeau J, Christodoulopoulos P, Maltais F, Yamauchi Y, Olivenstein R, Hamid Q. Effect of salmeterol/fluticasone propionate on airway inflammation in COPD: a randomised controlled trial. Thorax 2007;62:938-943. (Pubitemid 350084490)
22. Lindberg A, Szalai Z, Pullerits T, Radeczky E. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction. Respirology 2007;12:732-739. (Pubitemid 47414887)
23. Welte T, Miravitlles M, Peterson S, Polanowsi T, Kessler R. Budesonide/formoterol added to tiotropium improves the management of COPD patients [abstract]. Am J Respir Crit Care Med 2009;179:A6192.
24. Welte T, Hartman L, Polanowski T, Hernandez P. Budesonide/formoterol added to tiotropium is well tolerated and reduces risk of severe exacerbations in COPD patients [abstract]. Am J Respir Crit Care Med 2009;179:A6188.
25. Jones P, Spencer S, Adie S. The St George's respiratory questionnaire manual, version 2.1. London: St George's Hospital Medical School; 2003.
26. Partridge M, Karlsson N, Stahl E. Development of the Morning Activities and Symptoms Questionnaire (MASQ) for COPD. 251984. Eur Respir J 2008;32:814s.
27. Wedzicha JA, Calverley PM, Seemungal TA, Hagan G, Ansari Z, Stockley RA. The prevention of COPD exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med 2008;177:19-26.
28. Kardos P, Wencker M, Glaab T, Vogelmeier C. Impact of salmeterol/fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:144-149. (Pubitemid 46115085)
29. Tashkin DP, Rennard SI, Martin P, Ramachandran S, Martin UJ, Silkoff PE, Goldman M. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs 2008;68:1975-2000.
30. Rennard SI, Tashkin DP, McElhattan J, Goldman M, Silkoff PE. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs 2009;69:549-565.
31. Di Marco F, Milic-Emili J, Boveri B, Carlucci P, Santus P, Casanova F, Cazzola M, Centanni S. Effect of inhaled bronchodilators on inspiratory capacity and dyspnoea at rest in COPD. Eur Respir J 2003;21:86-94.
32. Harrison TW, Tattersfield AE. Plasma concentrations of fluticasone propionate and budesonide following inhalation from dry powder inhalers by healthy and asthmatic subjects. Thorax 2003;58:258-260.
33. Partridge M, Karlsson N, Small I. Patient insight into the impact of chronic obstructive pulmonary disease in the morning: an internet survey. Curr Med Res Opin 2009;25:2043-2048.
34. Partridge MR, Karlsson N. Patient insights on the impact of morning symptoms of COPD. Presented at the Sixth International Multidisciplinary Conference on COPD (COPD6), June 11-13, 2008, Birmingham, UK. P11.
35. Calverley PM, Lee A, Towse L, van Noord J, Witek TJ, Kelsen S. Effect of tiotropium bromide on circadian variation in airflow limitation in chronic obstructive pulmonary disease. Thorax 2003;58:855-860. (Pubitemid 37239232)
36. Suissa S, Ernst P, Vandemheen KL, Aaron SD. Methodological issues in therapeutic trials of COPD. Eur Respir J 2008;31:927-933.